注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Inventiva SA是一家从事生物技术业务的法国公司。该公司专注于肿瘤、纤维化和罕见疾病领域疗法的开发业务。该公司的产品线包括许多开发计划,如临床管线、临床前管线、艾伯维协作和勃林格殷格翰公司协作。它的候选药物针对非酒精性脂肪性肝炎(NASH)、系统性硬化症(SSc)、各种粘多糖贮积症(MPS)、多发性骨髓瘤、自身免疫性疾病以及肺癌等疾病。此外,该公司在众多领域提供从靶标识别到临床前提名的药物发现服务,如计算机模拟、生物学、筛选、吸收、分布、代谢和排泄(ADME)、药理和组织学。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Chris Buyse | 57 | 2017 | Independent Director |
Sven Francque | - | - | Member of Scientific Advisory Board |
Kenneth Cusi | - | - | Member of Scientific Advisory Board |
Manal Abdelmalek | - | - | Member of Scientific Advisory Board |
Glen Clack | - | - | Member of Scientific Advisory Board |
Jean-Louis Junien | 77 | 2016 | Chairman of Scientific Advisory Board |
Heinz Christoph Maeusli | 58 | 2019 | Independent Director |
Annick Schwebig | 70 | 2017 | Independent Director |
Xiaoqin Lu | 46 | 2018 | Independent Director |
Arun J. Sanyal | - | 2020 | Member of Scientific Advisory Board |
Andrew Shenker | 67 | 2019 | Member of Scientific Advisory Board |
Martine Zimmermann | 53 | 2021 | Independent Director |
Trever Bivona | - | 2022 | Member of the Scientific Advisory Board |
Elisabetta Bugianesi | - | 2022 | Member of the Scientific Advisory Board |
Gérard Zalcman | - | - | Scientific Advisory Board Member |
Frederic Cren | 58 | 2011 | Co-Founder, CEO & Chairman |
Pierre Broqua | 62 | 2011 | Co-Founder, Chief Scientific Officer, Deputy CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核